BioMarin's hemophilia gene therapy faces further delays over fresh FDA requests

Despite getting the green light in Europe this summer, BioMarin’s hopes for bringing its hemophilia gene therapy to the U.S. remain as distant as ever, with the FDA now requesting a look at its manufacturing site and long-term phase 3 data.